Corporate
Profile

[Company strength]
We worked with the three dimensional structure of proteins to develop a variant of Protein A that is both highly active and alkali stable. This was made possible by our in-house functional evaluation system, along with the technical know-how required to analyze the structure of modified proteins. We were then able to manufacture a variety of affinity media, by coupling the protein to solid phase resins. We have the technology in-house to handle everything from modifying proteins for high functionality to manufacturing the immobilizing resin. We also have the expertise needed for large-scale production of the recombinant protein from E. coli bacilli.

[Business description]
Our company engages in the bulk manufacture and sale of industrial use recombinant proteins. We have developed a variant with enhanced functionality by altering the amino acid sequence of the antibody binding protein, Protein A. This protein is indispensable in the manufacture of antibody drugs. We have succeeded in making this variant alkali tolerant, in addition to having high bonding strength, and are mass-producing and selling the product in bulk. This proprietary antibody binding protein, Protein A-R28, is alkali washable, enabling the manufacture of an affinity medium with high binding capacity that can be readily cleaned. We couple this protein to an immobilizing resin and sell it as Ab-Capcher, a product that excels in the purification of antibodies like immunoglobulin G

[Industry]
Manufacture of recombinant proteins

[Strength of products/technologies]
Antibody binding proteins typically used with immobilizing resins in the manufacturing of antibody drugs do not have strong alkali tolerance. This means that they cannot be subjected to alkali washing during drug production. We have a proven track record in developing and establishing mass production methods for a variant, Protein A-R28, which is alkali tolerant and has high binding capacity. We achieved this breakthrough by screening for recombinant variants of the amino acid sequence, based on the three dimensional structure of this protein.

[Representative's message]
We have been engaged, since our founding in 2005, in enhancing the functionality of antibody binding proteins through structural modification and bringing these advances to market. The 10th anniversary of our founding is now imminent, and our products have become adopted around the world. We intend to expand the business as we move ahead to have more resin chemical manufacturers, including those overseas, utilize our antibody binding proteins.

[Company structure for market development/overseas expansion]
Dedicated staff will serve as the portal for inquiries, with an engineer well versed in technical content placed in charge.

[Joint research and development]
Joint research in the development of antibody inducing drugs with Kyoto Pharmaceutical University and University of Tokushima

[Other sites]
Takamatsu Laboratory

[Transaction form]
Bulk protein supply, product joint development, contract manufacturing and sales

[Transaction terms]
Bulk proteins are sold directly, with payment under company terms and conditions after delivery and inspection. Ab-Capcher may be sold locally through agents as a research reagent.

[Main Clients / Business History (domestic)]
We supply the antibody binding protein we developed to several major chemical manufacturers. We also sell Ab-Capcher to drug, reagent and food manufacturers, and to various university and national public research institutions.

[Main Clients / Business History (overseas)]
We supply proteins in bulk to American life science companies, and sell Ab-Capcher to research institutions in the US, Europe and Asia.

[Exhibition History/Information]
Biotech 2013, Molecular Biology Society of Japan 2014 (planned)